D. K. Scott

429 total citations
13 papers, 336 citations indexed

About

D. K. Scott is a scholar working on Pharmacology, Pharmacology and Oncology. According to data from OpenAlex, D. K. Scott has authored 13 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 4 papers in Pharmacology and 3 papers in Oncology. Recurrent topics in D. K. Scott's work include Antibiotics Pharmacokinetics and Efficacy (5 papers), Pharmaceutical industry and healthcare (2 papers) and Chemotherapy-induced cardiotoxicity and mitigation (2 papers). D. K. Scott is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (5 papers), Pharmaceutical industry and healthcare (2 papers) and Chemotherapy-induced cardiotoxicity and mitigation (2 papers). D. K. Scott collaborates with scholars based in United Kingdom and United States. D. K. Scott's co-authors include R. Mark Leckie, W.J. Irwin, Michael Wood, R E Ferner, R. B. Hopkinson, A. P. Ball, Michael Snow, Richard J. Gilbert, Rajesh Paul and I. D. Farrell and has published in prestigious journals such as Journal of Antimicrobial Chemotherapy, British Journal of Clinical Pharmacology and QJM.

In The Last Decade

D. K. Scott

13 papers receiving 315 citations

Peers

D. K. Scott

AS

MB

NEURO

ECOLO

EP

Jan Roggeveld Netherlands

H. Herzog Germany

P Peura Finland

Tian Zhou China

Chenxi Shi China

Raymond G. York United States

E. Larson United States

Anne E. Loccisano United States

Fengju Li China

Marci G. Smeltz United States

Jan Roggeveld Netherlands

D. K. Scott

27 ×0.4

AS

48 ×0.9

MB

6 ×0.1

NEURO

72 ×1.4

ECOLO

3 ×0.1

EP

Citations per year, relative to D. K. Scott D. K. Scott (= 1×) peers Jan Roggeveld

Countries citing papers authored by D. K. Scott

Since Specialization

Citations

This map shows the geographic impact of D. K. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. K. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. K. Scott more than expected).

Fields of papers citing papers by D. K. Scott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. K. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. K. Scott. The network helps show where D. K. Scott may publish in the future.

Co-authorship network of co-authors of D. K. Scott

This figure shows the co-authorship network connecting the top 25 collaborators of D. K. Scott. A scholar is included among the top collaborators of D. K. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. K. Scott. D. K. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Ferner, R E & D. K. Scott. (1994). Whatalotwegot—the messages in drug advertisements. BMJ. 309(6970). 1734–1736. 17 indexed citations

2.

Scott, D. K. & R E Ferner. (1994). 'The strategy of desire' and rational prescribing.. British Journal of Clinical Pharmacology. 37(3). 217–219. 18 indexed citations

3.

Edwards, C. A., A. J. Bint, C W Venables, & D. K. Scott. (1992). Sampling time for serum gentamitin levels. Journal of Antimicrobial Chemotherapy. 29(5). 575–578. 3 indexed citations

4.

Wood, Michael, W.J. Irwin, & D. K. Scott. (1990). PHOTODEGRADATION OF DOXORUBICIN, DAUNORUBICIN and EPIRUBICIN MEASURED BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY. Journal of Clinical Pharmacy and Therapeutics. 15(4). 291–300. 52 indexed citations

5.

Wood, Michael, W.J. Irwin, & D. K. Scott. (1990). STABILITY OF DOXORUBICIN, DAUNORUBICIN and EPIRUBICIN IN PLASTIC SYRINGES and MINIBAGS. Journal of Clinical Pharmacy and Therapeutics. 15(4). 279–289. 37 indexed citations

6.

Scott, D. K. & R. Mark Leckie. (1990). Foraminiferal zonation of Great Sippewissett salt marsh (Falmouth, Massachusetts). The Journal of Foraminiferal Research. 20(3). 248–266. 78 indexed citations

7.

Scott, D. K. & C. A. Edwards. (1989). OPTIMIZATION OF BLOOD SAMPLING TIME AFTER INTRAVENOUS BOLUS DOSES OF GENTAMICIN. Journal of Clinical Pharmacy and Therapeutics. 14(1). 61–70. 2 indexed citations

8.

Gonda, Igor, et al.. (1984). Comparison of methods for estimating gentamicin clearance and retrospective analysis of changes in clearance with emphasis on patients with normal renal function.. British Journal of Clinical Pharmacology. 17(2). 147–155. 4 indexed citations

9.

Davey, Peter, et al.. (1983). Clinical experience with a method for adjusting gentamicin dose from measured drug clearance. Journal of Antimicrobial Chemotherapy. 12(6). 613–622. 6 indexed citations

10.

Westwood, Steven A., David E. Games, D. K. Scott, et al.. (1982). HPLC in pharmaceutical analysis. Analytical Proceedings. 19(3). 121–121. 22 indexed citations

11.

Gonda, Igor, et al.. (1980). REVIEW OF RECENT STUDIES ON CONTROL OF AMINOGLYCOSIDE ANTIBIOTIC THERAPY. Journal of Clinical Pharmacy and Therapeutics. 5(3). 175–195. 3 indexed citations

12.

Ball, A. P., R. B. Hopkinson, I. D. Farrell, et al.. (1979). Human Botulism Caused by Clostridium Botulinum Type E: The Birmingham Outbreak. QJM. 48(191). 473–91. 93 indexed citations

13.

Irwin, W.J., A. Li Wan Po, & D. K. Scott. (1979). THE STABILITY OF COMPOUND TABLETS CONTAINING ASPIRIN and PHENACETIN: THE EFFECT OF LEGISLATION. Journal of Clinical Pharmacy and Therapeutics. 4(1). 25–32. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact